Great Britain (GB)

 

Clinical Evidence

Clinical benefits for a broad range of T1D and T2D patients

A FreeStyle Libre System Healthcare Professional smiling.
A FreeStyle Libre System Healthcare Professional smiling.
A FreeStyle Libre System Healthcare Professional smiling.

Increased Monitoring Frequency

More frequent glucose monitoring with the FreeStyle Libre System is associated with better diabetes management1,5

A diagram showing that increased glucose monitoring frequency reduces hypoglycemia, increases TIR and decreases A1C. A diagram showing that increased glucose monitoring frequency reduces hypoglycemia, increases TIR and decreases A1C.

Reduced HbA1c

Use of the FreeStyle Libre portfolio of products is clinically proven to significantly reduce HbA1c in patients with T2D4,7

0.9% A1C reduction in patients with T2D icon. 0.9% A1C reduction in patients with T2D icon.
Overall, 0.9% HbA1c reduction in patients with T2D on basal bolus insulin4

(p<0.0001)

43% increase in time in target range icon. 43% increase in time in target range icon.
43% increase in time in target range

(3.9–10.0 mmol/L) from 11.7 to 16.8 hours a day with increased scan rate5
(p<0.001)

63% reduction in time spent in hyperglycemia icon. 63% reduction in time spent in hyperglycemia icon.
63% reduction in time spent in hyperglycaemia

across patients with T1D and T2D5
(p<0.001)

43% reduction in time spent in hyperglycemia icon. 43% reduction in time spent in hyperglycemia icon.
43% reduction in time spent in hypoglycaemia

in patients with T2D3
(p<0.001)

Making Better Choices

The FreeStyle Libre portfolio helps patients with T2D make better choices

Real World data showed that 95% of patients with T1D and T2D using the FreeStyle Libre system:

✓ Have a better understanding of their glucose fluctuations10

✓ Data from FreeStyle Libre users with T2D showed that users feel more engaged with managing their diabetes3,4

 

Lifestyle modifications can help lower HbA1c

Patients with T2D who make lifestyle changes, such as diet and physical activity, see improved glucose control.8

A woman and a man with mugs in their hands sitting at the table full of food. A woman and a man with mugs in their hands sitting at the table full of food. A woman and a man with mugs in their hands sitting at the table full of food.

Improve Glycaemic Control in ChildrenѰ

Children and teenagers can successfully improve their glycaemic control with the FreeStyle Libre 2 system

A child playing with a paper robot and man scanning the sensor on the child's arm. A child playing with a paper robot and man scanning the sensor on the child's arm.
Increase time in range by 1 hour per day icon. Increase time in range by 1 hour per day icon.

Increased time in range by 1 hour/day9 (3.9–10.0 mmol/L)

Reduced A1C by 0.4% icon. Reduced A1C by 0.4% icon.

Reduced HbA1c by 0.4%9

Average 13x per day icon. Average 13x per day icon.

Increased the frequency of glucose monitoring to an average of 13x /day vs. SMBG9

Reduced time spent in hyperglycemia icon. Reduced time spent in hyperglycemia icon.

Reduced time spent in hyperglycaemia

(>10 mmol/L) by 1 hr/day with no significant increase in time spent in hypoglycaemia (<3.9 mmol/L)9

90% of children and teenagers agreed that the FreeStyle Libre 2 system did not get in the way of daily activities icon. 90% of children and teenagers agreed that the FreeStyle Libre 2 system did not get in the way of daily activities icon.

90% of children and teenagers agreed that the FreeStyle Libre system did not get in the way of daily activities9

Additional Resources

Real-World Data

Analysing the impact of the FreeStyle Libre systems on the lives of real users.

EXPLORE REAL-WORLD DATA

Educational Modules

Learn more about Time in Range and the FreeStyle Libre 2 system through our Healthcare Professional education modules.

START LEARNING

Webinars

We offer various on-demand webinars for Healthcare Professionals including a spotlight on hypoglycaemia.

EXPLORE WEBINARS

      

Webcast Series

Learn more about Time in Range in our CME accredited three-module webcast series.

START THE SERIES

      

Training Resources

Explore our training resources to help you to help your patients understand Time in Range better.

EXPLORE TRAINING RESOURCES

References & Disclaimers

Images are for illustrative purposes only. Not real patient or data.

1. Dunn, T., et al. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Research and Clinical Practice; 137(2018) 37-46

2. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.

3. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55–73.

4. Kröger J, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther 2020;11(1):279–91.

5. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Poster 972]. Diabetes 2019 Jun; 68(Supplement 1). https://doi.org/10.2337/db19- 972-P.

6. Evans E, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1):83-95

7. Yaron M, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 2019;42(7):1178–84.

8. American Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45 (Suppl. 1):S60–S82

9. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study.
Pediatr Diabetes 2018;19(7):1294–301. 

10. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809

Ѱ. For children aged 4-12, a caregiver at least 18 years old is responsible for supervising, managing, and assisting them in using the FreeStyle Libre system and interpreting its readings.

Why FreeStyle Libre Systems?
FreeStyle Portfolio
Scientific Resources & Education
FreeStyle Portal
Help & Support
Abbott

FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorisation of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the UK. The product images are for illustrative purposes only.

©️ 2023 Abbott Laboratories Limited. All rights reserved.

Registered Number: 329102 England. Registered Office: Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE

Do you want to leave this page?

The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.

Do you want to leave this page?

Disclaimer

This is a product-specific website intended for HCPs of the European Union and the UK only. If you live in another country, please contact your local Abbott office to obtain the correct product information for your country of residence.